Skip to main content

The c-ret receptor tyrosine kinase as a target for drug discovery

Objective


The aim of this project is to generate a comprehensive platform of intellectual property to facilitate the discovery and development of a new generation of therapeutics with the ability to activate or inhibit the c-Ret receptor tyrosine kinase. Mutations in c-Ret are directly implicated in human cancers, and the c-Ret ligand, GDNF, is being developed as a therapeutic agent for neurodegenerative disorders such as Parkinson's disease and ALS. To develop c-Ret as a target for drug discovery we propose: i) to validate c-Ret as a drug target; ii) to develop scaleable assays for high throughput screening of c-Ret inhibitors and activators; iii) to isolate artificial c-Ret peptide ligands; iv) to determine the 3D structures of the extracellular and kinase domains of wild type and oncogenic c-Ret; v) to identify ligand binding sites in the c-Ret extracellular domain. Our long-term goal is to enter into license agreements with interested user groups for the exploitation of the generated knowledge and technology platform.

Call for proposal

Data not available

Coordinator

KAROLINSKA INSTITUTE
Address
Retzius Vaeg 8
171 77 Stockholm
Sweden

See on map

Links

Participants (3)

AUGUST KIRCHENSTEIN INSTITUTE OF MICROBIOLOGY AND VIROLOGY
Latvia
Address
Ratsupites 1
1067 Riga

See on map

Links
CANCER RESEARCH UK
United Kingdom
Address
Lincoln's Inn Field 61
WC2A 3PX London

See on map

Links
XERION PHARMACEUTICALS GMBH
Germany
Address
Fraunhoferstrasse 9
82152 Planegg / Krailling

See on map

Links